- The trend backdrop is active with a 17-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
SENORES
NSI
Week ended 07 Aug 2026
Weekly Investor Report
SENORES PHARMACEUTICALS L · Healthcare · Drug Manufacturers - General
Latest close
1,343 INR
2.9%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 33.1% above the Trend Line and sits at 81.0% of its 52-week range. The latest completed week returned 2.9%, after a -5.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 60/100. Near-term considerations: volume confirmation is below normal.
Setup score
66
out of 100
Latest Close
1,343 INR
7 Aug 2026
1W Return
2.9%
latest completed week
4W Return
-5.3%
short-term follow-through
12W Return
27.8%
quarterly tape
Trend Breadth
90.4%
47 of 52 weeks active
Volume Ratio
0.7x
vs 13-week average
- 5 reversal markers appear in the recent smart-money tape.
- Recent volatility is running well above the one-year baseline.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
2.9%
Latest completed week; four-week move -5.3%.
Indicator stack
95/65
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Positive 56.98%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
60/100
19 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 33.1% above the Trend Line and sits at 81.0% of its 52-week range. The latest completed week returned 2.9%, after a -5.3% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.9512-week average 0.90
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.95Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers55 reversal markers
No recent accumulation markers. 5 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -5.3% over four weeks, 27.8% over 12 weeks, and 105.8% over one year. The current trend has remained active for 17 consecutive weeks.
Performance by holding period
Active trend streak17 weeks
Active weeks in one year47
Trend breadth90.4%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.96Latest activity-pressure read.
Pressure change-31.5%Four-week change in activity pressure.
Leadership48.95Latest relative-leadership reading.
RS change-30.3%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 88%
Model confidence 82%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength34/100Blend of value, momentum, and quality. Underlying universe rank 67; rank 1 is best.
Value7/100Relative valuation strength. Underlying universe rank 94; rank 1 is best.
Quality66/100Profitability and accounting quality. Underlying universe rank 35; rank 1 is best.
Momentum98/100Medium-term price momentum. Underlying universe rank 3; rank 1 is best.
Growth97/100Revenue and earnings growth. Underlying universe rank 4; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework26/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 53.6x Price divided by trailing earnings.
- Price / sales
- 9.9x Market value relative to trailing revenue.
- EV / EBITDA
- 30.2x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -3.1% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 59.8% Gross profit retained from each unit of revenue.
- Operating margin
- 23.7% Operating profit retained from revenue.
- Free-cash-flow margin
- -32.4% Free cash flow generated from revenue.
- Return on invested capital
- 9.1% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 58.9% Latest one-year revenue growth.
- EPS growth
- 97.0% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 7/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -0.4% Net share repurchases relative to market value.
- Shareholder yield
- -0.4% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.4x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment60/100
Weighted news tone is neutral across 19 relevant articles.
7 positive · 12 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-11.1%Distance below the 52-week high.
13-week volatility7.9%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher15 of 2611 weeks finished lower.
Best week+24.7%Week of 12 Jun.
Worst week-7.7%Week of 5 Jun.
Latest week+2.9%Week of 7 Aug.
Shape of recent returns
Strong gains8
Modest gains7
Flat weeks0
Modest losses7
Sharp losses4
Recent vol7.9%13-week weekly-return volatility.
Base vol5.6%52-week weekly-return volatility.
Up/down split32/20Count of positive and negative weeks in the 52-week window.
Average skew4.8% / -3.7%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank81 / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - General
4-week rank9 / 11
Group average2.2%
Trend breadth72.7%
Trend72.7%active weekly trend signals
MD81.8%positive activity pressure
RS72.7%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape70/100
Trend, activity pressure, participation, and risk combine to a 70/100 tape read.
Indicator analysis82/100Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.
Activity pressure 0.95; 5 reversal markers Next-Week ExpectancyPositive 56.98%Next-week expectancy is positive with a 56.98% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors49/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 82; Small Cap Core rank 97 SVQF26/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 1172.5 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment60/100Weighted news tone is neutral across 19 relevant articles.
Senores Pharmaceuticals - Retail investors raised stakes in 12 smallcap stocks that surged up to 110% Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 1,343 INR | 2.9% | 1,009 INR | 772.2 INR | 0.96 | 48.95 | 1.0M | On |
| 31 Jul 2026 | 1,305 INR | -5.9% | 991.2 INR | 765.4 INR | 1.21 | 48.05 | 2.1M | On |
| 24 Jul 2026 | 1,388 INR | -1.3% | 976.6 INR | 758.8 INR | 1.38 | 63.80 | 1.1M | On |
| 17 Jul 2026 | 1,405 INR | -0.9% | 957.5 INR | 751.0 INR | 1.40 | 64.81 | 1.2M | On |
| 10 Jul 2026 | 1,418 INR | 2.6% | 937.5 INR | 742.9 INR | 1.40 | 70.23 | 1.9M | On |
| 3 Jul 2026 | 1,382 INR | 8.8% | 916.5 INR | 734.3 INR | 1.39 | 68.71 | 601.9K | On |
| 26 Jun 2026 | 1,270 INR | -3.4% | 896.3 INR | 726.0 INR | 1.24 | 59.55 | 0 | On |
| 19 Jun 2026 | 1,315 INR | 1.9% | 881.4 INR | 719.0 INR | 1.29 | 68.54 | 185.6K | On |
| 12 Jun 2026 | 1,290 INR | 24.7% | 864.9 INR | 711.1 INR | 1.36 | 71.52 | 1.3M | On |
| 5 Jun 2026 | 1,035 INR | -7.7% | 847.9 INR | 703.4 INR | 1.42 | 41.83 | 113.5K | On |
| 29 May 2026 | 1,121 INR | 0.9% | 840.9 INR | 698.9 INR | 1.56 | 54.62 | 981.0K | On |
| 22 May 2026 | 1,111 INR | 5.8% | 829.2 INR | 693.1 INR | 1.49 | 54.73 | 6.4M | On |
| 15 May 2026 | 1,050 INR | 8.8% | 817.8 INR | 687.3 INR | 1.34 | 49.26 | 3.8M | On |
| 8 May 2026 | 965.5 INR | 7.4% | 806.6 INR | 682.2 INR | 1.16 | 36.36 | 1.2M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.